Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has been assigned an average rating of “Hold” from the ten research firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $5.63.
A number of analysts recently issued reports on the company. Zacks Investment Research cut Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. BidaskClub raised Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 21st. Chardan Capital reissued a “neutral” rating on shares of Achillion Pharmaceuticals in a research note on Sunday, September 17th. Finally, Leerink Swann reissued a “buy” rating and set a $5.00 target price on shares of Achillion Pharmaceuticals in a research note on Monday, December 11th.
Achillion Pharmaceuticals (NASDAQ:ACHN) traded up $0.02 during midday trading on Monday, reaching $2.99. The company had a trading volume of 1,235,318 shares, compared to its average volume of 1,943,265. Achillion Pharmaceuticals has a twelve month low of $2.69 and a twelve month high of $5.66. The company has a market cap of $412.19, a PE ratio of -6.10 and a beta of 1.52.
In related news, major shareholder & Johnson Johnson sold 18,367,346 shares of the stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $2.75, for a total transaction of $50,510,201.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.24% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. RTW Investments LP grew its stake in shares of Achillion Pharmaceuticals by 392.9% during the 3rd quarter. RTW Investments LP now owns 7,839,766 shares of the biopharmaceutical company’s stock worth $35,201,000 after acquiring an additional 6,249,312 shares in the last quarter. Janus Henderson Group PLC bought a new position in shares of Achillion Pharmaceuticals during the 2nd quarter worth approximately $20,778,000. Dimensional Fund Advisors LP grew its stake in shares of Achillion Pharmaceuticals by 75.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,276,076 shares of the biopharmaceutical company’s stock worth $14,710,000 after acquiring an additional 1,407,108 shares in the last quarter. Sarissa Capital Management LP bought a new position in shares of Achillion Pharmaceuticals during the 3rd quarter worth approximately $9,594,000. Finally, FMR LLC grew its stake in shares of Achillion Pharmaceuticals by 11.0% during the 2nd quarter. FMR LLC now owns 1,603,622 shares of the biopharmaceutical company’s stock worth $7,361,000 after acquiring an additional 159,218 shares in the last quarter. 76.92% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Brokerages Set Achillion Pharmaceuticals, Inc. (ACHN) PT at $5.63” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://stocknewstimes.com/2018/01/11/brokerages-set-achillion-pharmaceuticals-inc-achn-pt-at-5-63.html.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.